References
- KesslerCMcgonagleKASwartzMBlazerDGNelsonBSex and depression in the National Comorbidity Survey I: lifetime prevalence chronicity and recurrenceJ Affect Disord19932985968300981
- World Health Organization Depression [webpage on the Internet]GenevaWorld Health Organization2018Accessed May 3, 2018 Available from: http://www.who.int/en/news-room/fact-sheets/detail/depression
- SmithDDempsterCGlanvilleJFreemantleNAndersonIEfficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysisBr J Psychiatry200218039640411983635
- ThaseMEHaightBRRichardNRemission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trialsJ Clin Psychiatry200566897498116086611
- TrivediMHRushAJWisniewskiSREvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284016390886
- FavaMDavidsonKGDefinition and epidemiology of treatment-resistant depressionPsychiatr Clin North Am19961921792008827185
- NierenbergAAFarabaughAHAlpertJETiming of onset of antidepressant response with fluoxetine treatmentAm J Psychiatry200015791423142810964858
- SzegediAJansenWTvan WilligenburgAPvan der MeulenEStassenHHThaseMEEarly improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patientsJ Clin Psychiatry200970334435319254516
- NemeroffCBPrevalence and management of treatment-resistant depressionJ Clin Psychiatry2007688172517640154
- BlierPRational site-directed pharmacotherapy for major depressive disorderInt J Neuropsychopharmacol2014177997100823745670
- KennedySHLamRWMcIntyreRSCanadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Section 3. Pharmacological treatmentsCan J Psychaitry2016619540560
- CleareAParianteCMYoungAHEvidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelinesJ Psychopharmacol201529545952525969470
- KellerMLavoriPMuellerTTime to recovery, chronicity, and levels of psychopathology in MDD – 5-year follow-upArch Gen Psychiatry1992498098161417434
- OlubokaOJKatzmanMAHabertJFunctional recovery in major depressive disorder: providing early optimal treatment for the individual patientInt J Neuropsychopharmacol201821212814429024974
- MaesMLibbrechtIvan HunselFCampensDMeltzerHYPindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistanceJ Clin Psychopharmacol199919217718210211920
- NelsonJCMazureCMJatlowPIBowersMBPriceLHCombining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized studyBiol Psychiatry200455329630014744472
- BlierPGobbiGTurcotteJEMirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiationEur Neuropsychopharmacol200919745746519345072
- BlierPWardHETremblayPLabergeLHébertCBergeronRCombination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized studyAm J Psychiatry2010167328128820008946
- RushAJTrivediMHStewartJWCombining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized studyAm J Psychiatry2011168768970121536692
- StewartJWMcGrathPJBlondeauCCombination antidepressant therapy for major depressive disorder: speed and probability of remissionJ Psychiatr Res201452171424485847
- CorpIBMIBM SPSS Statistics for Windows, Version 22.0Armonk, NYIBM Corp Released 2013
- WadeAGCrawfordGMYellowleesAEfficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot studyBMC Psychiatry20111114221410960
- GuerdjikovaAIMcelroySLKotwalRHigh-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trialHum Psychopharmacol200823111118058852
- RabinowitzIBaruchYBarakYHigh-dose escitalopram for the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol2008231495318090508
- DoughertyDDJamesonMDeckersbachTOpen-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol200924630631119730388
- ShimGParkHYJangJHWhat is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label studyInt Clin Psychopharmacol201126528429021829108
- VincentSBieckPRGarlandEMClinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profilesCirculation2004109253202320715184278
- BattenLAHernandezMPilowskyDJChildren of treatment-seeking depressed mothers: a comparison with the sequenced treatment alternatives to relieve depression (STAR*D) child studyJ Am Acad Child Adolesc Psychiatry201251111185119623101744
- HensslerJBschorTBaethgeCCombining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patientsCan J Psychiatry2016611294327582451